Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Potent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans

Saturday, April 18, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: ENTA's EPS-3903, a potent STAT6 inhibitor, has demonstrated excellent preclinical pharmacokinetics. This allows for sustained inhibition of STAT6 with a convenient once-daily oral dosing regimen in humans. The findings suggest promising therapeutic potential for this compound in treating related conditions.
Price reaction · baseline $14.01 (2026-04-17 close) · 2 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • EPS-3903 shows excellent preclinical pharmacokinetics.
  • Enables sustained STAT6 inhibition with once-daily dosing.
  • Potential for effective treatment in humans.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EPS-3903?

EPS-3903 is a potent STAT6 inhibitor developed by ENTA.

What are the dosing requirements for EPS-3903?

EPS-3903 allows for once-daily oral dosing in humans.

What does the preclinical data suggest?

The preclinical data indicates excellent pharmacokinetics for EPS-3903.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EPS-3903 STAT6 pharmacokinetics preclinical
Last updated: Apr 18, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →